Clinical trial · Observational
Positive ER Expression Assessed by 18F-FES PET/CT in the MBC with ER-negative Primary Tumor
Positive Estrogen Receptor (ER) Expression Assessed by 18F-fluoroestradiol Positron Emission Tomography/Computed Tomography (18F-FES PET/CT) in the Metastatic Breast Cancer (MBC) with ER- Negative Primary Tumor
NCT06344767CI-TRIAL-00081403completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To investigate the treatment pattern and efficacy of patients with negative primary ER lesion but positive ER expression in MBC using a novel convenient way of 18F-fluoroestradiol positron emission tomography/computed tomography (18F-FES PET/CT).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- FES positive in MBC
- description
- Patients who did not present with any ER-positive lesions in primary cancer were characterized as with any positive ER expression in the metastatic stage
Primary outcomes (1)
- measure
- Progression free survival (PFS)
- timeFrame
- 6 weeks
- description
- Progression free survival
Secondary outcomes (1)
- measure
- Adverse events
- timeFrame
- 6 weeks
- description
- Number of participants with treatment-related adverse events as assessed by CTCAE v 5.0
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients diagnosed with breast cancer (according to International Classification of Diseases 10th Revision) with confirmed metastasis, regardless of being de novo diagnosed or progressed from a nonmetastatic stage. * MBC patients who underwent 18F-FES PET/CT at the Fudan University Shanghai Cancer Center between 2012 and 2023 * Patients diagnosed with primary ER-negative tumor and who were yet to receive any systemic therapy during the advanced stage Exclusion Criteria: Patients with incomplete medical records and those diagnosed with secondary primary tumors
References
Publications (0)
Data not yet available
No reference posted for this study.